Rani Therapeutics (RANI) H.C. Wainwright 28th Annual Global Investment Conference summary

Technology and innovation

• Developed a platform for oral delivery of biologics with bioavailability comparable to subcutaneous injections, using the RaniPill, a swallowable auto-injector that delivers drugs pain-free through the gut wall.

• Demonstrated ability to deliver monoclonal antibodies and large proteins, with preclinical studies showing equivalent or superior bioavailability to injections.

Strategic partnerships and validation

• Secured a multi-target, billion-dollar potential partnership with Chugai, following two years of diligence and successful molecule testing.

• Chugai added five option agreements for high-value immunology targets, totaling up to $900 million in potential payments.

• The Chugai partnership catalyzed a $60 million PIPE financing, bringing in new institutional investors.

Business model and portfolio strategy

• Pursues a partnering business model, licensing technology or products to large pharma for late-stage development and commercialization.

• Focuses on rare diseases and immunology, leveraging partners' expertise for clinical studies and commercialization.

• Maintains flexibility to run early-stage studies internally, especially in immunology and obesity, before seeking partners.